
Science Resources RSS Feeds
|
 |
 |
 |
Purdue findings reveal possible Alzheimer's link to brain organ
March 22, 2006
Researchers have discovered that an organ in the brain called the choroid plexus apparently plays a critical role in preventing the accumulation of a protein associated with Alzheimer's disease. The researchers found that the choroid plexus acts as a sort of "fishnet" that captures the protein, called beta-amyloid, and prevents it from building up in the cerebrospinal fluid, which surrounds and bathes the brain and spinal cord. Moreover, tissue in the organ is able to soak up large amounts of the protein and may contain enzymes capable of digesting beta-amyloid, said Wei Zheng (pronounced Way Zsheng), an associate professor in the School of Health Sciences at Purdue University.
The findings represent the first time that researchers have identified the potential existence of a natural mechanism in the brain for removing beta-amyloid.
"This newly uncovered pathway may help explain how normal brains balance this protein and how an imbalance caused by aging, genetic or environmental factors may lead to or worsen Alzheimer's disease," Zheng said.
Researchers had already known that the cerebrospinal fluid in the brains of Alzheimer's patients contains abnormally high quantities of beta-amyloid fragments. Beta-amyloid deposits accumulate over a period of years, resulting in abnormal clumps, or plaque, typical of Alzheimer's disease. Scientists do not yet know whether the disease is caused by the plaque formations or beta-amyloids themselves.
The discovery suggests that a malfunctioning choroid plexus could allow too much of the protein to build up in the brain.
Findings are detailed in a research paper written by postdoctoral research associate Janelle S. Crossgrove, postdoctoral fellow G. Jane Li and Zheng, all in the Purdue School of Health Sciences. The researchers will be honored on April 2 with a best paper award from the Society for Experimental Biology and Medicine.
Scientists do not know how beta-amyloid is deposited in the brains of Alzheimer's disease victims, but a long-held theory is that the protein is overproduced by aging brain cells, or neurons.
"We are coming from a totally different point of view," Zheng said. "We think that a balance of beta-amyloid is maintained partly by the choroid plexus, which removes beta-amyloid, and that this balance breaks down, leading to a buildup."
The majority of Alzheimer's research has historically concentrated on how the brain produces beta-amyloid protein, but the new findings point to the possibly critical importance of the "garbage-removal" process in the choroid plexus, Zheng said.
"We think the choroid plexus plays a role of removing all the garbage, including the beta-amyloid," Zheng said.
The research focused on how the choroid plexus works to clean beta-amyloid from the cerebrospinal fluid. Studies using rat brains indicated that choroidal cells removed about five times more beta-amyloid from cerebrospinal fluid compared to how much of the protein the cells allowed to pass into the fluid.
"These results appear to tell us that a healthy choroid plexus can remove beta-amyloid from the cerebrospinal fluid, suggesting a novel pathway for the brain to maintain a normal balance," Zheng said. "Of course, much more work needs to be done to verify this theory."
The researchers also found that the choroid plexus possesses an enormous capacity to absorb beta-amyloids. The findings support the theory that the choroid plexus may possess a special enzyme that breaks beta-amyloids into smaller pieces, making it possible to soak up large quantities of the protein.
"The tissue must have a unique mechanism that is different from brain cells, something that enables it to chop up these beta-amyloids," Zheng said.
Future research may focus on efforts to isolate possible enzymes.
Zheng said the findings suggest that aging may degrade the organ's performance, and it is also possible that lead poisoning might increase the risk of Alzheimer's disease by damaging the choroid plexus and reducing its ability to filter beta-amyloids.
Alzheimer's disease affects more than 4 million Americans, and the findings might help researchers develop new methods to treat the disease. The research paper was published last November in the journal Experimental Biology and Medicine.
Purdue University
|
 |
Related Beta-amyloid Current Events and Beta-amyloid News Articles Beta-amyloid Current Events and Beta-amyloid News RSS New findings about brain proteins suggest possible way to fight Alzheimer's The action of a small protein that is a major villain in Alzheimer's disease can be counterbalanced with another brain protein, researchers at UT Southwestern Medical Center have found in an animal study.
Oleocanthal may help prevent, treat Alzheimer's Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells.
University Hospitals Case Medical Center to test gammaglobulin treatment for Alzheimer's disease Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin.
New marker for Alzheimer's discovered Gothenburg researchers have discovered a previously unknown substance in spinal fluid that can be used to diagnose Alzheimer's disease.
Study shows how to boost value of Alzheimer's-fighting compounds The polyphenols found in red wine are thought to help prevent Alzheimer's disease, and new research from Purdue University and Mount Sinai School of Medicine has shown that some of those compounds in fact reach the brain.
Breakthrough in Alzheimer's research A combination of proteins in the cerebrospinal fluid can reliably identify which patients with early symptoms of dementia will subsequently develop full-blown Alzheimer's disease, a research team at the University of Gothenburg, Sweden, has found in a major international study.
Barrow researchers identify new brain receptor, possible target for Alzheimer's treatment Barrow Neurological Institute researchers have identified a novel receptor in the brain that is extremely sensitive to beta-amyloid peptide (AB) and may play a key role in early stages of Alzheimer's disease.
Brain imaging and proteins in spinal fluid may improve Alzheimer's prediction and diagnosis Changes in the brain measured with MRI and PET scans, combined with memory tests and detection of risk proteins in body fluids, may lead to earlier and more accurate diagnosis of Alzheimer's.
Mount Sinai researchers find new Alzheimer's disease treatment promising Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer's disease.
New study provides further evidence that apple juice can delay onset of Alzheimer's disease A growing body of evidence demonstrates that we can take steps to delay age-related cognitive decline, including in some cases that which accompanies Alzheimer's disease, according to a study published in the January 2009 issue of the Journal of Alzheimer's Disease. More Beta-amyloid Current Events and Beta-amyloid News Articles
|
 |

|
Alzheimer's Disease: Cellular and Molecular Aspects of Amyloid beta (Subcellular Biochemistry)
by Robin Harris (Editor), Falk Fahrenholz (Editor)
Preface: To understand Alzheimer?s disease (AD) is one of the major thrusts of present-day clinical research, strongly supported by more fundamental cellular, biochemical, immunological and structural studies. It is these latter that receive attention within this book. This compilation of 20 chapters indicates the diversity of work currently in progress and summarizes the current state of knowledge. Experienced authors who are scientifically active in their fields of study have been selected as contributors to this book, in an attempt to present a reasonably complete survey of the field. Inevitably, some exciting topics for one reason or another have not been included, for which we can only apologize. Standardization of terminology is often a problem in science, not least...
|
![[beta]-amyloid Peptide (1-42), Human, Oncogene - Size 250 Ug - Model Pp69--25mg - Each (.25 Mg)](http://ecx.images-amazon.com/images/I/31Y1NF0J0EL._SL160_.gif)
|
[beta]-amyloid Peptide (1-42), Human, Oncogene - Size 250 Ug - Model Pp69--25mg - Each (.25 Mg)
by Oncogene
[beta]-Amyloid Peptide (1-42), Human, Oncogene - Size 250 ug - Model PP69--25MG - Each (.25 MG) : Lyophilized.Synthetic peptide corresponding to amino acids 1-42 of the processed human amyloid peptide. Supplied in a form that is not neurotoxic prior to preincubation. The level of toxicity has recently been shown to correlate to the extent of beta sheet structure. Reconstitute with degassed HPLC grade deionized water. Purity: >95% by HPLC. FW: 4 kDa.
|
|
|
Nerve link: Alzheimer's suspect shows up in glaucoma.(This Week)(amyloid beta-protein): An article from: Science News
by N. Seppa (Author)
This digital document is an article from Science News, published by Thomson Gale on August 11, 2007. The length of the article is 483 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Nerve link: Alzheimer's suspect shows up in glaucoma.(This Week)(amyloid beta-protein) Author: N. Seppa Publication: Science News (Magazine/Journal) Date: August 11, 2007 Publisher: Thomson Gale Volume: 172 Issue: 6 Page: 84(2)
Distributed by Thomson...
|

|
Amyloid Proteins: The Beta Sheet Conformation and Disease
by Jean D. Sipe (Editor)
A first-stop reference on proteins associated with amyloidosis. This book is the first to present a systematic overview of all known fibril-forming proteins, including their biochemical characteristics and pathophysiology. It considers the clinically recognized amyloid proteins that are known to be associated with the amyloid protein folding disorders, dealing with their common structural and thermodynamic features that lead to amyloid fibril formation and disease. Emphasis is on the thermodynamics of protein folding, the structure and physiologic effects of common oligomeric and subfibrillar intermediates and the influence of the extracellular matrix and cellular trafficking and metabolism on the genesis and catabolism of beta pleated sheet proteins. The chapters on...
|
|
|
PET scans show [beta]-Amyloid, promise early Alzheimer's Dx. (Very Preliminary Data).: An article from: Family Practice News
by Miriam E. Tucker (Author)
This digital document is an article from Family Practice News, published by International Medical News Group on September 15, 2002. The length of the article is 468 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: PET scans show [beta]-Amyloid, promise early Alzheimer's Dx. (Very Preliminary Data). Author: Miriam E. Tucker Publication: Family Practice News (Magazine/Journal) Date: September 15, 2002 Publisher: International Medical News Group Volume: 32 Issue: 18 Page: 2(1)
Distributed by Thomson...
|
|
|
Beta amyloid: the peptide that kills from both the outside and inside to produce Alzheimer's disease. (Collegiate Communications--Undergraduate).(Brief ... of the North Dakota Academy of Science
by Jason Spah (Author), Katherine Splichal (Author), Kali Wilson (Author), Garl K. Rieke (Author)
This digital document is an article from Proceedings of the North Dakota Academy of Science, published by North Dakota Academy of Science on April 1, 2000. The length of the article is 897 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Beta amyloid: the peptide that kills from both the outside and inside to produce Alzheimer's disease. (Collegiate Communications--Undergraduate).(Brief Article) Author: Jason Spah Publication: Proceedings of the North Dakota Academy of Science (Refereed) Date: April 1, 2000 Publisher: North Dakota Academy of Science Page:...
|
|
|
Brain sabotage: Alzheimer's protein may spawn miniseizures.(This Week)(Amyloid beta-protein): An article from: Science News
by N. Seppa (Author)
This digital document is an article from Science News, published by Thomson Gale on September 15, 2007. The length of the article is 536 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Brain sabotage: Alzheimer's protein may spawn miniseizures.(This Week)(Amyloid beta-protein) Author: N. Seppa Publication: Science News (Magazine/Journal) Date: September 15, 2007 Publisher: Thomson Gale Volume: 172 Issue: 11 Page: 165(2)
Distributed by Thomson...
|
|
|
Genetic variant tied to amyloid-[beta] generation in Alzheimer's.(Geriatric Psychiatry)(Clinical report): An article from: Clinical Psychiatry News
by Jeff Evans (Author)
This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on April 1, 2007. The length of the article is 763 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Genetic variant tied to amyloid-[beta] generation in Alzheimer's.(Geriatric Psychiatry)(Clinical report) Author: Jeff Evans Publication: Clinical Psychiatry News (Magazine/Journal) Date: April 1, 2007 Publisher: Thomson Gale Volume: 35 Issue: 4 Page: 25(1)
Article Type: Clinical report
Distributed by Thomson...
|
|
|
Low plasma [beta]-amyloid levels may be a marker for cognitive decline.(Geriatric Psychiatry): An article from: Clinical Psychiatry News
by Kerri Wachter (Author)
This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on October 1, 2005. The length of the article is 595 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Low plasma [beta]-amyloid levels may be a marker for cognitive decline.(Geriatric Psychiatry) Author: Kerri Wachter Publication: Clinical Psychiatry News (Magazine/Journal) Date: October 1, 2005 Publisher: Thomson Gale Volume: 33 Issue: 10 Page: 48(1)
Distributed by Thomson...
|
|
|
FDG-PET scan targets [beta]-amyloid deposits. (May Predict Alzheimer's).: An article from: Internal Medicine News
by Miriam E. Tucker (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on September 1, 2002. The length of the article is 485 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: FDG-PET scan targets [beta]-amyloid deposits. (May Predict Alzheimer's). Author: Miriam E. Tucker Publication: Internal Medicine News (Magazine/Journal) Date: September 1, 2002 Publisher: International Medical News Group Volume: 35 Issue: 17 Page: 4(1)
Distributed by Thomson...
|
|